Novotech has experience in over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. Novotech is positioned to serve biotech clients conducting clinical trials in Asia Pacific, the US and Europe. Novotech has over 3000 staff globally and 34 office locations.
Novotech provides clinical development services across all clinical trial including regulatory and drug development consulting, protocol design and writing, feasibility assessments, local ethics committee and regulatory submissions, clinical monitoring, project and vendor management, data management, statistical analysis, data visualization and analytics, DCTs, medical advisory and medical monitoring, pharmacovigilance, central lab services and clinical study report writing. We work to the highest quality standards, in line with ICH-GCP, global regulatory agencies and underpinned by robust processes in line with our ISO 9001 accredited Quality Management system.
Novotech has broad therapeutic experience with a particular focus on oncology/immuno-oncology, infectious disease/vaccines, neurology, and rare diseases.
As a biotech specialist, Novotech has extensive medical, scientific, regulatory, and operational expertise with advanced and novel therapeutics, across all therapeutic areas, including cell & gene therapies, precision medicine, RNA based vaccines and therapeutics, ADCs, microbiome, radiopharmaceuticals and more.
Our geographic presence, our depth of expertise and services, our operational infrastructure, and investments in technological advancements, combine to provide the perfect solution to accelerate global clinical development for biotech Sponsors.
Our Culture
Our values and our people is what makes Novotech a great place to work
Our work culture is driven by our values, every day.
Performance Passion
Making it happen, doing it well and owning the outcome
Uncompromised Integrity
We never hesitate to say or do the right thing
Open Engagement
How we work together recognizes the value of everyone involved through open communication
Unlocking Talent
We are all responsible for developing our people
Our mission is to help bring advances in therapeutic products to market efficiently by providing high quality clinical development services to our clients. We will do this by hiring and developing highly talented people, employing the best technologies in our operations, and by fostering a culture of open communication, teamwork and sharing of knowledge, experience and resources with our internal and external partners.
A horizontal organisational structure that encourages inter-country and inter-department collaboration and knowledge-sharing is paramount. We are proud of our inclusive culture and committed to always looking for ways to improve and remain a leader in workplace flexibility and gender equality. We are continually making progress
Board of Directors
Dr. Anand Tharmaratnam
Anand brings over 20 years of experience in global drug development and the CRO industry. He was previously the president of Asia Pacific at IQVIA. Anand is a medical doctor by training and graduated from the University College London, UK and trained in the anaesthesia.
Mr. Joel Thickins
Joel is a Partner at TPG Capital and leads the firm’s investment program in the ANZ region as Head of Australia and New Zealand. Joel has previously served on the board of Inghams Group Limited and Accolade Wines Holding Australia Pty Limited.
Before joining TPG, Joel was a director at CPE Capital (formerly known as CHAMP Private Equity) where he was responsible for the company’s activities in the industrial, agricultural services and consumer markets.
Dr. Fred Cohen
Fred Cohen is a Senior Advisor to TPG and was a partner and co-founder of TPG Biotech. Fred has served on the board of several biotech and pharmaceutical organizations including BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) and CareDx, Inc. (NASDAQ: CDNA)
Mr. Vincent Wong
Vincent Wong is Partner with TPG Capital and is based in Melbourne, where he works in TPG’s Australian team. Vincent also serves on the board of other TPG investments such as Invocare, iNova, and Funlab. Prior to joining TPG in 2011, Vincent served in the corporate advisory division at Goldman Sachs Australia. Vincent graduated from the University of Melbourne with BCommerce and BLaws (Honors).
Ms. Cai Li (蔡俐)
Lydia Cai is a Managing Director with TPG Capital based in Beijing and leads TPG’s healthcare investments in the Greater China area. Prior to joining TPG in 2011, Lydia was an investment associate at HAO Capital, a China-focused early stage private equity fund focusing on growth-stage healthcare investments.
Dr. John Moller
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
Ms. Elaine Cheung (張綺玲)
Ms. Cheung is responsible for providing independent advice to the Board. She chairs the Audit Committee. Ms. Cheung has more than 30 years of corporate experience in the Asia-Pacific region. In January 1990, Ms. Cheung graduated from San Francisco State University with a bachelor of science degree, majoring in business administration.
Senior Management
Dr. John Moller
John joined Novotech in January 2014 to lead the development of Novotech’s Asia operations. Prior to Novotech John was Managing Director of IVF Australia and Queensland Fertility Group and sat on the Board of Virtus Health Limited. John is a medical doctor by training.
Michael Stibilj
Michael has 25 years of experience in the CRO Industry. Prior to joining Novotech in 2017, Michael spent 15 years building and leading operations across Asia for Quintiles/IQVIA, and was senior advisor for TPG Capital.
Dr. Judith Ng-Cashin
Judith joined Novotech in 2023 bringing 20 years of international pharmaceutical, biotech and CRO experience, including multiple senior executive roles, including CMO and CSO roles. Judith, based in the US, is driving Novotech’s global multi-regional later-phase strategy as well as ensuring high quality delivery of medical services to our clients and patients.
Barry Murphy
Barry joined in July 2014 to lead the growth of Novotech’s Business Development team. Barry started his career as a pharmacist having graduated from the University of Dublin. He has held multiple contract management roles at ICON plc.
Rob Speedie
Rob was most recently a Managing Director in the TPG Capital Operations Team and lead a number of Strategic Initiatives across TPG’s portfolio, including time as the CPOO at Greencross. Prior to TPG, Rob was a Partner at PwC where he spent a total of 19 years. His roles at PWC included 10 years as a Transaction Services professional and 10 years in audit services across Australia, Asia and US. He worked in a range of industries including the pharmaceutical sector. Rob acted as Investigating Accountant and Signing Partner on multiple IPOs on the ASX, was a member of PwCs technical accounting issues escalation committee and has significant experience in financial due diligence.
Veronica Holloway
Veronica joined Novotech in May 2014 to formalise the legal function at Novotech. Prior to Novotech, Veronica held roles as Senior Legal Counsel at EY, Senior Solicitor at Clayton Utz and General Counsel (on secondment) at Novartis Pharmaceuticals Australia Pty Limited. Veronica holds a BA/LLB/LLM.
Angela Edwardson
Angela joined Novotech in November 2015 and is responsible for Novotech's Human Resources operations including strategy, organisational development, remuneration & reward and workplace health and safety. Angela is passionate about delivering Novotech's vision of being the leading CRO in the Asia Pacific region.
Andy Liu
Andy worked at Covance, Inc., a global CRO, for more than 10 years in a number of executive positions. Most recently, he was General Manager of Covance's Central Laboratory Service, Asia Pacific, where he led a large multi-functional team of across multiple sites in APAC. Andy holds an MBA from the University of Chicago, an MS in Electrical Engineering from the Rose-Hulman Institute of Technology, and a BS in Electrical Engineering from Tsinghua University.
Iain Gordon
Iain, with over 20 years of experience in CRO management and corporate development in Europe and North America, joined EastHORN in 2013 as Chief Business Officer. He played a vital role in the company's growth. He has held senior management positions, including European Head and Global VP of Business Development, in the global CRO industry. In 2021, he succeeded Dr. Alan Wood as Executive Chairman, ensuring the company's growth continued apace. After the 2023 merger with Novotech, Iain became Managing Director of Novotech Europe and sits on their Executive Board. Based in the UK, he holds a degree in Cell Biology from the University of Glasgow.
Rick Farris
Rick joined Novotech in 2023 with over 22 years of clinical research experience and over 30 years in the life sciences. His clinical research career has been focused wholly on serving the unique needs and challenges of biotech clients. Rick has worked in executive leadership roles in 3 global CROs, leading operations teams and helping organizations build global project support capabilities.
Dr. Yooni Kim
Dr. Yooni Kim is Managing Director APAC at Novotech with over 25 years of clinical research experience and technical knowledge in CRO, Pharmaceutical and Academic Research.
With a Ph.D. in Preventive Medicine (Epidemiology) from the Seoul National University of Medicine, she started her career at GSK in 2004 and joined ICON Clinical Research (ex-PRA) in 2009 as Director of Operations.
Dr. Yooni worked with PRA Health Sciences for seven years, establishing the legal entity and service capabilities for PRA Korea. Since joining Novotech in 2016, she has provided exemplary service as the Executive Director Asia Operations before being appointed her current position of Managing Director APAC at Novotech.
